Integrated Clinical Systems, Inc. announced the opening of a European branch office in Switzerland
Integrated Clinical Systems, Inc. (ICS) www.i-review.com, developers of Integrated Review™ & JReview®, the world’s most comprehensive clinical review and analysis software tool, today announced the opening of a European branch office in Switzerland. The office will be the company’s first location in Europe, dedicated to client management and business development in Europe, Middle East & Africa (EMEA).
ICS’s EMEA branch office is located in Lausanne, Switzerland. It will be led by Dr. Mark Demesmaeker, Director of EMEA & Asia Operations, who joined the company in January from TIBCO Spotfire where he headed the clinical analytics practice.
Eric S. Herbel, President of ICS said, “Our European customers have been frequently asking for an ICS regional presence and support. As a consequence, we have decided to set up a European branch office in order to better serve our European customers and also expand our footprint in the EMEA region.”
“About 40% of our customer base is located in Europe and the business is constantly growing” says Dr. Demesmaeker. “Many of our clients are global corporations with regional headquarters. Expanding and scaling a high-quality customer service and business development team is a key driver to our continued success in the market.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.